Table 1 Rh110 (pp71) deletion reduces dissemination of RhCMV vectors.

(A) Three RhCMV-naïve RMs (T1A-1, T1A-2, and T1A-3) were co-inoculated with 107 PFU each of 68-1/SIVgag (left arm) and ΔRh110/SIVrtni (right arm). One RM each was necropsied at 14, 21, or 28 dpi, and viral genome copy numbers per 107 cell equivalents were determined in the indicated tissues using ultrasensitive nested qPCR specific for SIVgag (68-1) or SIVrtni (ΔRh110). (B) Three naturally RhCMV-infected RMs (T1B-1, T1B-2, and T1B-3) were co-inoculated with 107 PFU each of 68-1/SIVrtni (left arm) and ΔRh110/SIVgag (right arm). One RM each was necropsied at 14, 21, or 28 dpi, and viral genome copy numbers per 107 cell equivalents in the indicated tissues were determined using ultrasensitive nested qPCR specific for SIVgag (ΔRh110) or SIVrtni (68-1). (C) Two naturally RhCMV-infected RMs (T1C-1 and T1C-2) were co-inoculated with 107 PFU each of complemented ΔRh110 and uncomplemented ΔRh110 in different arms, with the SIVgag and SIVrtni inserts used to mark the complemented and uncomplemented vectors, respectively, in RM1 and the reverse in RM2. Both RMs were necropsied at 14 dpi, and viral genome copy numbers were determined using ultrasensitive nested qPCR specific for SIVgag versus SIVrtni. Normalized to 1 × 107 cell equivalents. WT, wild type; GI, gastrointestinal; LN, lymph node; PLN, parietal lymph node.

A. Primary infection: 68-1 versus ΔRh110
RM T1A-1RM T1A-2RM T1A-3
Tissue type14 dpi21 dpi28 dpi
68-1/SIVgagΔRh110/SIVrtni681/SIVgagΔRh110/
SIVrtni
68-1/SIVgagΔRh110/
SIVrtni
Skin injection site—right (ΔRh110)19,975,462<113,2272<1<1
Skin injection site—left (WT)1,013,192,441314,453<1<1<1
Axillary LN—right
(ΔRh110 draining)
4,547<1<1<17<1
Axillary LN—left (WT draining)17,687,789<129,484<15,771<1
PLN (except draining LN)265,298493<140<1
Mesenteric LN<115<15<1
GI tract3458<164<1
Liver/gallbladder11<1<1<141<1
Heart/lung/kidney/BAL66477<1<1<1
BM/spleen/tonsil439,736<1<1<1
Neuro/endocrine14<18<1<1<1
Genitourinary tract1251414,075<117<1
Salivary glands13,262<11,242<111<1
PBMCs<13<1<1<1<1
B. Superinfection: 68-1 versus ΔRh110
RM T1B-1RM T1B-2RM T1B-3
Tissue type14 dpi21 dpi28 dpi
68-1/SIVrtniΔRh110/SIVgag68-1/SIVrtniΔRh110/
SIVgag
68-1/SIVrtniΔRh110/
SIVgag
Skin injection site—right (WT)47516,502<1376<1
Skin injection site—left (ΔRh110)113547<1355<1
Axillary LN—right
(WT draining)
117<17<1509<1
Axillary LN—left
(ΔRh110 draining)
<1<1<1<1<1<1
Peripheral LN1,434<141<12<1
Mesenteric LN<111<1<1<1
GI tract3<1<1<112<1
Liver/gallbladder1<19<19<1
Heart/lung/kidney/BAL5<1<1<18<1
BM/spleen/tonsil155<1<1<1<1
Neuro/endocrine<1<13<13<1
Genitourinary tract3<14<11,047<1
Salivary gland231<1<1<1<1
C. ΔRh110: Complemented versus uncomplemented
RM T1C-1←14 dpi→RM T1C-2
Tissue typeUncomplemented
ΔRh110/SIVrtni
Complemented
ΔRh110/SIVgag
Tissue typeUncomplemented
ΔRh110/SIVgag
Complemented
ΔRh110/SIVrtni
Skin injection site—right
(complemented)
<1<1Skin injection site—right
(uncomplemented)
<1<1
Skin injection site—left
(uncomplemented)
13<1Skin injection site—left
(complemented)
<1<1
Axillary LN—right
(complemented draining)
<1<1Axillary LN—right
(uncomplemented
draining)
<1<1
Axillary LN—left
(uncomplemented draining)
17<1Axillary LN—left
(complemented
draining)
<1<1
PLN (except draining LN)<1<1PLN (except draining
LN)
<1<1
Mesenteric LN<1<1Mesenteric LN<1<1
GI tract<1<1GI tract<1<1
Liver/gallbladder<1<1Liver/gallbladder<1<1
Heart/lung/kidney/BAL<1<1Heart/lung/kidney/BAL<1<1
BM/spleen/tonsil<1<1BM/spleen/tonsil<1<1
Neuro/endocrine<1<1Neuro/endocrine<1<1
Genitourinary tract5<1Genitourinary tract<12
Salivary glands<1<1Salivary glands<1<1
PBMCs<1<1PBMCs<1<1